(Q34688511)

3 August 2017

1 reference

title

The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators (English)

1 reference

3 August 2017

1 reference

1 reference

2

V Craig Jordan

1 reference

3 August 2017

Ruth M O'Regan

1

1 reference

3 August 2017

language of work or name

1 reference

1 April 2002

1 reference

Lancet Oncology Commission

3 August 2017

published in

1 reference

3 August 2017

volume

3

1 reference

3 August 2017

issue

4

1 reference

3 August 2017

page(s)

207-214

1 reference

Tamoxifen: a personal retrospective.

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

A new derivative of triphenylethylene: effect on implantation and mode of action in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

Synthetic oestrogens in mammary cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

Anti-oestrogen Therapy for Breast Cancer: A Trial of Tamoxifen at Two Dose Levels

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

The development of tamoxifen for breast cancer therapy: a tribute to the late Arthur L. Walpole

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

Tamoxifen in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

Effects of anti-estrogens on bone in castrated and intact female rats

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

Effects of tamoxifen on spinal bone density in women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

Effects of tamoxifen on cardiovascular risk factors in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

Phase II Evaluation of Lyl56758 in Metastatic Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

Inhibition of the uterotropic activity of estrogens and antiestrogens by the short acting antiestrogen LY117018

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

Cloning of a novel receptor expressed in rat prostate and ovary

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

The oestrogen-like effect of 4-hydroxytamoxifen on induction of transforming growth factor alpha mRNA in MDA-MB-231 breast cancer cells stably expressing the oestrogen receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

Molecular basis of agonism and antagonism in the oestrogen receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

Structural insights into the mode of action of a pure antiestrogen

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

Regulation of prolactin synthesis in vitro by estrogenic and antiestrogenic derivatives of estradiol and estrone

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

Possible mechanisms in the emergence of tamoxifen-resistant breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic acid: a non-steroidal estrogen with functional selectivity for bone over uterus in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

Steroidal pure antioestrogens

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

Aromatase inhibitors in the treatment and prevention of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900711-8

7 January 2021

10.1016/S1470-2045(02)00711-8

Identifiers

DOI

1 reference

3 August 2017

1 reference